ArticleInternational journal of surgery (London, England)2025
Thoracoscopic surgical ablation for atrial fibrillation patients with functional regurgitation: the treatment strategy prioritizing atrial fibrillation.
Article in International journal of surgery (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Commentary on "Thoracoscopic surgical ablation for atrial fibrillation patients with functional regurgitation: the treatment strategy prioritizing atrial fibrillation".International journal of surgery (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial fibrillation (AF) and functional regurgitation (FR) have complex interactions. This study investigated the interactions between thoracoscopic surgical ablation (TSA) and FR in patients with AF, to explore whether the strategy prioritizing AF can treat FR, thus avoiding additional valve surgeries.
methodsA total of 152 AF patients underwent isolated TSA were included for a 12-month follow-up. Among them, the control group contains 67 patients with no valve disease, and the FR group contains 85 patients diagnosed as functional mitral regurgitation (FMR, n = 50) and/or functional tricuspid regurgitation (FTR, n = 75). The changes in the degrees of regurgitation, the recurrence rate of AF 12 months after surgery, and the occurrence of cardiac reverse remodeling were statistically analyzed. Logistic regression analyses were performed to identify variables associated with the reduction in regurgitation.
resultsThe difference in 12-month sinus rhythm (SR) maintenance rate between the FR group and the control group was not significant (61.18% vs. 74.62%, P = 0.08). FMR degree was reduced significantly ( P < 0.05) while FTR degree was not ( P = 0.66), and the reduction in FTR is related to the reduction in FMR (OR = 19.80, 95% CI 2.22-176.60, P < 0.05) among the patients with both. Significant cardiac reverse remodeling and heart function improvement were observed after TSA (e.g. preoperative vs. postoperative: LV: 47.82 ± 5.37 mm vs. 46.52 ± 5.17 mm, P < 0.05; LA: 42.73 ± 5.41 mm vs. 40.79 ± 6.57 mm, P < 0.05). Logistic regression analyses revealed that the variation in left ventricular posterior wall, the variation in pulmonary artery pressure (PAP) and SR maintenance are associated with FMR reduction ( P < 0.05), while preoperative interventricular septum, the variation in PAP and preoperative FTR degree are associated with FTR reduction ( P < 0.05).
conclusionsThe treatment strategy prioritizing AF is reasonable for patients with AF and FMR. The existence of mild to moderate FR cannot affect TSA results, while TSA can reduce the degree of FMR through cardiac reverse remodeling. And the reduction in FTR is secondary to the PAP decrease after FMR reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.